ClinicalTrials.gg

Program

safusidenib

Also written as “Safusidenib”, “DS-1001b” and “AB-218 capsule”.

Its studies are mostly in Glioma · Oligodendroglioma · Astrocytoma · Cholangiocarcinoma, led by 2 companies.

Furthest: phase 3, since Mar 13, 20226 company-led studies, 4 open or runningNext primary completion: Dec 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nuvation Bio43 open or runningphase 3since Mar 13, 2022Mar 13, 2022Dec 1, 2028phase 3 · NCT05303519
Daiichi Sankyo21 open or runningphase 2since Jun 29, 2020Jan 18, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2017First study: phase 1 study in GliomaNew to Daiichi SankyoDaiichi Sankyo · NCT03030066 · 47 enrolled · Japan
  2. Jun 29, 2020Phase 2 study in GliomaDaiichi Sankyo · NCT04458272 · 25 enrolled · Japan
  3. Mar 13, 2022Nuvation Bio’s first study: phase 3 study in GliomaNew to Nuvation BioNuvation Bio · NCT05303519 · 365 planned · United States, Australia, China
  4. Mar 20, 2023Phase 1 study in Cholangiocarcinoma With IDH1 MutationNuvation Bio · NCT05814536 · 9 enrolled · China
  5. Jul 9, 2026Phase 3 study in AstrocytomaNuvation Bio · NCT07712757 · 140 planned
  6. Jul 9, 2026Phase 2 study in GliomaNuvation Bio · NCT07703436 · 40 planned · United States

Ahead

  1. Dec 1, 2028Primary completion: phase 3 study in GliomaNuvation Bio · NCT05303519
  2. May 2029Primary completion: phase 3 study in AstrocytomaNuvation Bio · NCT07712757
  3. Sep 2030Primary completion: phase 2 study in GliomaNuvation Bio · NCT07703436

TargetBeta

IDH1 →read by rule
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
olutasidenibruleRigel Pharmaceuticalsphase 45
ivosidenibruleAgios Pharmaceuticalsphase 313
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
IDH1 Inhibitor TQB3454Sino Biopharmaceuticalphase 35

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07712757Astrocytoma3Not yet recruitingNuvation BioMay 2029140
NCT07703436Glioma · United States2RecruitingNuvation BioSep 203040
NCT05814536Cholangiocarcinoma With IDH1 Mutation · China1TerminatedNuvation BioAug 15, 20249
NCT05303519Glioma · United States, Australia, China3RecruitingNuvation BioDec 1, 2028365
NCT04458272Glioma · Japan2Active, not recruitingDaiichi SankyoMar 10, 202325
NCT03030066Glioma · Japan1CompletedDaiichi SankyoJan 31, 202147

How it is read

Names in the registry

  • “Safusidenib”, 2 entries
  • “DS-1001b”, 2 entries
  • “safusidenib”, 1 entry
  • “AB-218 capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.